Denmark· DK-28106666621

Thiotepa "Abcur"

A thiotepa product containing thiotepa, registered in Denmark by Abcur AB. The same ATC class is registered in 16 of our 19 countries.

ATC L01AC01

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedThiotepa "Abcur"ATCL01AC01REGISTER NO.DK-28106666621PACKS LISTED1CHECKEDSeptember 30, 2026

Where it is registered

Thiotepa is registered in 16 of 19 countries.

Countries holding a registration under ATC L01AC01 (thiotepa), each read from that country’s own register.

  • This record: Denmark, from Danish Medicines Agency (Denmark)
  • 9 of them publish a price we can compare per daily dose

Thiotepa · ATC L01AC01

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
THIOTEPA
Manufacturer
Abcur AB
Country
Denmark (DK)
ATC code
L01AC01
ATC class
Thiotepa
Defined daily dose
1.62 g, P
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28106666621

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

202 interactions on record for thiotepa.

Graded by severity as the source publishes them — 43 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Thiotepa · interactions on record

202 records

  • 43 severe
  • 105 moderate
  • 14 minor
  • 40 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • CyclophosphamideL01AA01severe
  • ChlorambucilL01AA02severe
  • MelphalanL01AA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/78fd59ae-d5e5-4278-ac92-cfe52aff16e6
GET /v1/drugs/78fd59ae-d5e5-4278-ac92-cfe52aff16e6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "pulver til koncentrat til infusionsvæske, opløsning",
  "source": "dkma",
  "strength": "15 mg",
  "auth_role": "CMS",
  "dk_drugid": "28106666621",
  "substance": "THIOTEPA",
  "auth_procedure": "Decentral procedure",
  "in_medicinpriser": false,
  "registration_date_serial": "45281"
}

See everything about thiotepa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.